ArticlesUrsodeoxycholic acid (cas 128-13-2) versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial
-
Add time:09/25/2019 Source:sciencedirect.com
SummaryBackgroundIntrahepatic cholestasis of pregnancy, characterised by maternal pruritus and increased serum bile acid concentrations, is associated with increased rates of stillbirth, preterm birth, and neonatal unit admission. Ursodeoxycholic acid is widely used as a treatment without an adequate evidence base. We aimed to evaluate whether ursodeoxycholic acid reduces adverse perinatal outcomes in women with intrahepatic cholestasis of pregnancy.
We also recommend Trading Suppliers and Manufacturers of Ursodeoxycholic acid (cas 128-13-2). Pls Click Website Link as below: cas 128-13-2 suppliers
Prev:Original articleAdherence to Ursodeoxycholic acid (cas 128-13-2) therapy in patients with cholestatic and autoimmune liver disease
Next:Enzymatic routes for the synthesis of Ursodeoxycholic acid (cas 128-13-2)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research ArticleUrsodeoxycholic acid (cas 128-13-2) therapy and liver transplant-free survival in patients with primary biliary cholangitis09/28/2019
- Original articleEffect of oral Ursodeoxycholic acid (cas 128-13-2) on cholelithiasis following laparoscopic sleeve gastrectomy for morbid obesity10/01/2019
- Ursodeoxycholic acid (cas 128-13-2) is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH09/27/2019
- Enzymatic routes for the synthesis of Ursodeoxycholic acid (cas 128-13-2)09/26/2019
- Original articleAdherence to Ursodeoxycholic acid (cas 128-13-2) therapy in patients with cholestatic and autoimmune liver disease09/24/2019
- Anticholestatic mechanisms of Ursodeoxycholic acid (cas 128-13-2) in lipopolysaccharide-induced cholestasis09/10/2019
- Ursodeoxycholic acid (cas 128-13-2) and cancer: From chemoprevention to chemotherapy09/09/2019
-
Health and Chemical more >